# XTOP Biotherapeutics

Source: https://onco.cc/companies/xtop-biotherapeutics/  
OnCo record `xtop-biotherapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

XTOP Biotherapeutics is a Worcester, Massachusetts company that designs antibodies binding three targets at once to steer T cells onto cancer cells. Its lead, CB-101, is aimed at colon, pancreatic and lung cancers.

## Summary

XTOP Biotherapeutics Inc., of Worcester, Massachusetts, builds multispecific antibodies on its CrossBody platform, which it says lets it tune tumour and T-cell binding to reduce the risk of cytokine release syndrome and conceal tumour-antigen binding to limit toxicity in normal tissue. Its lead, CB-101, is described as a trispecific T-cell engager for colon, pancreatic and lung cancers; the company also announced a research collaboration with Daiichi Sankyo. In fiscal year 2026 the National Cancer Institute funded its SBIR project on CB-101, a trispecific antibody targeting ROR1, EpCAM and CD3 for colorectal cancer and other solid tumours (1R43CA310454-01A1, USD 400,000).

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: XTOP BIOTHERAPEUTICS INC.
- HQ: Worcester, MA
- Type: biotech
- Website: https://www.xtopbiotherapeutics.com/

## Notes

- Read on xtopbiotherapeutics.com (home and pipeline pages) and the NIH RePORTER record on 4 November 2026. The targets of CB-101 are from the award title; the website does not name them.

## Sources

- Official website: https://www.xtopbiotherapeutics.com/
- Pipeline: https://www.xtopbiotherapeutics.com/pipeline/pipeline
- NIH RePORTER: 1R43CA310454-01A1: https://reporter.nih.gov/project-details/11407471

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/), [Trispecific antibodies](https://onco.cc/technologies/trispecific-antibodies/)
- targets: [CD3](https://onco.cc/targets/cd3/), [EpCAM](https://onco.cc/targets/epcam/), [ROR1](https://onco.cc/targets/ror1/)
- drugs: [CB-101](https://onco.cc/drugs/cb-101/)

---
JSON: https://onco.cc/api/v1/entities/xtop-biotherapeutics.json